Latest Breaking News On - Motor function measure - Page 9 : comparemela.com
Taysha takes over development of giant axonal neuropathy gene therapy
scienceboard.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceboard.net Daily Mail and Mail on Sunday newspapers.
Taysha Dishes Out $5 5 Million for Rare Disease Gene Therapy
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Progra
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
April 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Apr 8, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus ® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, Enspryng™ (sat
PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. We are happy to see the rapid adoption of Evrysdi in the EU which speaks to the need for new treatments for SMA patients, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. We are delighted that an effective at-home therapy will be available to SMA patients. We recognize that a large proportion of SMA patients in the EU are current